NCT00165399View on ClinicalTrials.gov

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Adenocarcinoma of the ProstateProstate Cancer
Interventions
DRUG

Docetaxel

Given intravenously on day 2 of four three-week cycles

DRUG

Estramustine

Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)

DRUG

Casodex

Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months

DRUG

Zoladex

Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.

Trial Locations (5)

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01805

Lahey Clinic-Burlington, Burlington

01655

University of Massachusetts Memorial Medical Center-University Campus, Worcester

037566-0002

Norris Cotton Cancer Center, Lebanon

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT00165399 - Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | Biotech Hunter | Biotech Hunter